Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri(®)) Dosing: NOVA Phase IIIb Extension Study (Part 2)
每 6 周一次的纳他珠单抗 (Tysabri®) 给药方案中,患者对皮下注射与静脉注射的偏好:NOVA IIIb 期扩展研究(第 2 部分)
期刊:Neurology and Therapy
影响因子:4.8
doi:10.1007/s40120-024-00647-0
Wiendl, Heinz; Foley, John; Defer, Gilles; Zhovtis Ryerson, Lana; Cohen, Jeffrey A; Arnold, Douglas L; Butzkueven, Helmut; Cutter, Gary R; Giovannoni, Gavin; Killestein, Joep; Domingo-Horne, Rose; Toukam, Marie; Nunn, Aimie; Maghzi, Amir-Hadi; Kuhelj, Robert; Lasky, Tyler